Chronic Kidney Disease: A Comprehensive Review

Year : 2025 | Volume : 03 | Issue : 01 | Page : 37 42
    By

    Ritu,

  • Anshika Rosha,

  1. Assistant Professor, Department of Nursing, Galgotias School of Nursing, Galgotias University, Uttar Pradesh, India
  2. Nursing Tutor, Department of Nursing, Galgotias School of Nursing, Galgotias University, Uttar Pradesh, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_200546’);});Edit Abstract & Keyword

Chronic Kidney Disease (CKD) is a progressive condition characterized by a long-term decline in kidney function, leading to a gradual deterioration of the kidneys’ ability to filter waste and maintain fluid balance. It is diagnosed when the Glomerular Filtration Rate (GFR) falls below 60 ml/min/1.73 m² or when there is evidence of kidney damage (such as proteinuria) lasting for 3 months or more. The most common causes of CKD are chronic conditions such as diabetes and hypertension, which contribute to the damage of the kidney’s structures over time. As the disease advances, CKD can lead to several complications that impact overall health. Anemia, often due to reduced erythropoietin production by the kidneys, and cardiovascular diseases, including hypertension and heart failure, are prevalent in CKD patients. Furthermore, if left untreated, CKD may progress to end-stage renal disease (ESRD), where kidney function becomes critically low, and the patient may require dialysis or a kidney transplant to sustain life. Early detection of CKD is essential for effective management. Routine screening for individuals at risk, such as those with diabetes, hypertension, or a family history of kidney disease, is recommended. Treatment strategies focus on controlling the underlying causes, such as blood pressure and blood sugar management, alongside lifestyle changes, including dietary modifications and weight management. Medical interventions, such as medications to manage symptoms and slow the progression of the disease, also play a key role in preserving kidney function and preventing the need for more intensive treatments like dialysis.

Keywords: Chronic Kidney Disease (CKD), Glomerular Filtration Rate (GFR), End-stage Renal Disease (ESRD), hypertension, anemia

[This article belongs to International Journal of Emergency and Trauma Nursing and Practices ]

How to cite this article:
Ritu, Anshika Rosha. Chronic Kidney Disease: A Comprehensive Review. International Journal of Emergency and Trauma Nursing and Practices. 2025; 03(01):37-42.
How to cite this URL:
Ritu, Anshika Rosha. Chronic Kidney Disease: A Comprehensive Review. International Journal of Emergency and Trauma Nursing and Practices. 2025; 03(01):37-42. Available from: https://journals.stmjournals.com/ijetnp/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_200546’);});Edit

References

  1. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010 Aug 13; 329(5993):841– doi: 10.1126/science.1193032. Epub 2010 Jul 15. PMID: 20647424; PMCID: PMC2980843.
  2. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010 Sep; 128(3): 345– doi: 10.1007/s00439-010-0861-0. Epub 2010 Jul 16. PMID: 20635188; PMCID: PMC2921485.
  3. Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, Young BA, Lettre G, Peralta CA, Katz R, Hyacinth HI, Quarells RC, Grove ML, Bick AG, Fontanillas P, Rich SS, Smith JD, Boerwinkle E, Rosamond WD, Ito K, Lanzkron S, Coresh J, Correa A, Sarto GE, Key NS, Jacobs DR, Kathiresan S, Bibbins-Domingo K, Kshirsagar AV, Wilson JG, Reiner AP. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014 Nov 26;312(20): 2115– doi: 10.1001/jama.2014.15063. PMID: 25393378; PMCID: PMC
    4356116.
  1. O’Seaghdha CM, Parekh RS, Hwang SJ, et al. The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet. 2011; 20(12): 2450–2456.
  2. Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016; 27(9): 2842–2850. doi: 10.1681/ASN.2015070763
  3. Peralta CA, Vittinghoff E, Bansal N, et al. Trajectories of kidney function decline in young black and white adults with preserved GFR: results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Kidney Dis. 2013; 62(2): 261–266.
  4. Grams ME, Chow EK, Segev DL, Coresh J. Lifetime incidence of CKD stages 3–5 in the United States. Am J Kidney Dis. 2013; 62(2): 245–252. doi: 10.1053/j.ajkd.2013.03.
  5. Matsushita K, Coresh J, Sang Y, et al. CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015; 3(7): 514–525. doi: 10.1016/S2213-8587(15)00040-6
  6. Fu Z, Geng X, Chi K, Song C, Wu D, Liu C, HongEfficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med.2021; 10(7): 7428–7439. https://doi.org/10.21037/apm-21-763
  7. Guillermo García-García, Alfonso Gutierrez-Padilla, Raul Reyna-Raygoza, Carlos Rosales-Galindo, Margarita Ibarra-Hernandez, Karina Renoirte-Lopez. Chapter 30: CKD Screening in Mexico. In: Chronic Kidney Disease in Disadvantaged Populations. Academic Press; 2017; 323–328. com. Retrieved November 23, 2024, from https://www.sciencedirect.com/science/article/abs/pii/B9780128043110000303
Regular Issue Subscription Review Article
Volume 03
Issue 01
Received 03/02/2025
Accepted 10/02/2025
Published 05/08/2025
Publication Time 183 Days
99

[first_name] [last_name]

My IP

PlumX Metrics